RESUMEN
The Innovative Medicine Initiative (IMI) is a joint technology initiative jointly implemented by the European Commission and by the European Federation of Pharmaceutical Industries and Associations (EFPIA). The objective of IMI, officially launched on April 30th 2008, is to identify and address the bottlenecks of the drug discovery and development process. IMI will reinforce the public-private partnerships and will be focused towards critical nodes of the drug discovery such as efficacy predictivity, safety predictivity, knowledge management and education and training. This initiative will also reinforce the attractivity of Europe for biomedical science and will then lead to the discovery of novel therapeutic strategies for the patients.
Asunto(s)
Descubrimiento de Drogas/organización & administración , Sistemas de Registro de Reacción Adversa a Medicamentos , Biotecnología/organización & administración , Ensayos Clínicos como Asunto , Conducta Cooperativa , Diseño de Fármacos , Evaluación Preclínica de Medicamentos , Industria Farmacéutica/organización & administración , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Europa (Continente) , Agencias Gubernamentales/organización & administración , Humanos , Sector Privado/organización & administración , Sociedades/organización & administraciónRESUMEN
The intersection of two noble endeavors - the scientists' quest to understand life itself and the physicians' dedication to relieve suffering and prolong life - came into sharp focus in 1971 with the United States National Cancer Act. This focus has led to an exponential expansion of our understanding of cancer at the genetic, molecular and cellular levels, and concomitant advances in our ability to disrupt the disease process through prevention, early detection and successful treatment. At the National Cancer Institute we are committed to capitalize on these achievements. A new era is now within our grasp, a time when no one suffers or dies as a result of cancer.
Asunto(s)
National Institutes of Health (U.S.)/organización & administración , Neoplasias , Animales , Biotecnología/organización & administración , Biotecnología/tendencias , Instituciones Oncológicas/organización & administración , Quimioprevención , Ensayos Clínicos como Asunto , Biología Computacional/organización & administración , Evaluación Preclínica de Medicamentos , Perfilación de la Expresión Génica , Objetivos , Humanos , Ratones , Neoplasias/diagnóstico , Neoplasias/epidemiología , Neoplasias/genética , Neoplasias/prevención & control , Neoplasias/terapia , Proteómica , Investigación/organización & administración , Estados UnidosRESUMEN
No disponible
No disponible